

# Francisco Cervantes Requena

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8456879/publications.pdf>

Version: 2024-02-01

239  
papers

28,384  
citations

28190

55  
h-index

5227

165  
g-index

243  
all docs

243  
docs citations

243  
times ranked

14675  
citing authors

#	ARTICLE	IF	CITATIONS
1	Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2003, 348, 994-1004.	13.9	3,227
2	Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2006, 355, 2408-2417.	13.9	3,212
3	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , 2013, 122, 872-884.	0.6	1,743
4	JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. <i>New England Journal of Medicine</i> , 2012, 366, 787-798.	13.9	1,543
5	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2009, 27, 6041-6051.	0.8	1,188
6	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2006, 108, 1809-1820.	0.6	1,184
7	New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. <i>Blood</i> , 2009, 113, 2895-2901.	0.6	1,110
8	Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. <i>Nature Genetics</i> , 2010, 42, 722-726.	9.4	1,034
9	DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. <i>Journal of Clinical Oncology</i> , 2011, 29, 392-397.	0.8	854
10	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. <i>Blood</i> , 2007, 110, 1092-1097.	0.6	808
11	A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). <i>Blood</i> , 2010, 115, 1703-1708.	0.6	805
12	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2011, 29, 761-770.	0.8	724
13	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. <i>Blood</i> , 2007, 110, 3540-3546.	0.6	688
14	Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. <i>Blood</i> , 2007, 109, 2303-2309.	0.6	563
15	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i> , 2018, 32, 1057-1069.	3.3	415
16	Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. <i>Blood</i> , 2013, 122, 4047-4053.	0.6	383
17	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. <i>JAMA Oncology</i> , 2015, 1, 643.	3.4	362
18	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. <i>Blood</i> , 2014, 124, 1062-1069.	0.6	340

#	ARTICLE	IF	CITATIONS
19	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). <i>Blood</i> , 2006, 108, 1497-1503.	0.6	317
20	Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). <i>Leukemia Research</i> , 2007, 31, 737-740.	0.4	288
21	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. <i>Blood</i> , 2013, 122, 1395-1398.	0.6	286
22	Outcome of Transplantation for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 358-367.	2.0	245
23	SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor- Na <sup>+</sup> ve Patients With Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2017, 35, 3844-3850.	0.8	243
24	EZH2 mutational status predicts poor survival in myelofibrosis. <i>Blood</i> , 2011, 118, 5227-5234.	0.6	242
25	Thrombosis in primary myelofibrosis: incidence and risk factors. <i>Blood</i> , 2010, 115, 778-782.	0.6	216
26	Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2009, 27, 4563-4569.	0.8	213
27	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2018, 5, e73-e81.	2.2	211
28	Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. <i>Journal of Hematology and Oncology</i> , 2017, 10, 156.	6.9	210
29	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. <i>Haematologica</i> , 2015, 100, 1139-1145.	1.7	203
30	Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. <i>Haematologica</i> , 2006, 91, 169-75.	1.7	199
31	Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. <i>British Journal of Haematology</i> , 1998, 102, 684-690.	1.2	168
32	Identification of "short-lived" and "long-lived" patients at presentation of idiopathic myelofibrosis. <i>British Journal of Haematology</i> , 1997, 97, 635-640.	1.2	164
33	Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. <i>Blood</i> , 2010, 116, 2857-2858.	0.6	153
34	Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. <i>Blood</i> , 2015, 125, 3347-3350.	0.6	152
35	Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 1992, 81, 391-394.	1.2	140
36	Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. <i>British Journal of Haematology</i> , 2002, 118, 786-790.	1.2	135

#	ARTICLE	IF	CITATIONS
37	Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. <i>Annals of Hematology</i> , 2010, 89, 1233-1237.	0.8	134
38	How I treat myelofibrosis. <i>Blood</i> , 2014, 124, 2635-2642.	0.6	132
39	Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. <i>British Journal of Haematology</i> , 2004, 127, 399-403.	1.2	125
40	Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. <i>British Journal of Haematology</i> , 2005, 129, 771-775.	1.2	122
41	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. <i>Haematologica</i> , 2016, 101, 926-931.	1.7	118
42	Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and <i>JAK2 V617F</i> allele burden. <i>American Journal of Hematology</i> , 2009, 84, 102-108.	2.0	116
43	Improving Survival Trends in Primary Myelofibrosis: An International Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2981-2987.	0.8	105
44	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. <i>American Journal of Hematology</i> , 2014, 89, 732-742.	2.0	102
45	Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. <i>Blood</i> , 2014, 123, 1833-1835.	0.6	95
46	Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. <i>Blood</i> , 2014, 124, 729-736.	0.6	84
47	Does ruxolitinib prolong the survival of patients with myelofibrosis?. <i>Blood</i> , 2017, 129, 832-837.	0.6	81
48	"Lymphoid" blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. <i>British Journal of Haematology</i> , 1998, 100, 129-134.	1.2	79
49	Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. <i>Blood</i> , 2014, 123, 3803-3810.	0.6	79
50	Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). <i>Blood</i> , 2005, 106, 2849-2853.	0.6	75
51	Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. <i>British Journal of Haematology</i> , 2013, 162, 229-239.	1.2	75
52	Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2015, 62, 72-74.	1.8	72
53	Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2006, 134, 184-186.	1.2	67
54	Association Between EZH2 and Other Acquired Mutations In Myelofibrosis and Myelodysplastic/Myeloproliferative Neoplasms. <i>Blood</i> , 2010, 116, 625-625.	0.6	64

#	ARTICLE	IF	CITATIONS
55	Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. <i>Annals of Hematology</i> , 2015, 94, 1791-1796.	0.8	57
56	Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. <i>British Journal of Haematology</i> , 1994, 88, 117-121.	1.2	56
57	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 151-159.	0.8	56
58	The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2138-2149.	3.3	55
59	Deoxycoformycin in the treatment of patients with hairy cell leukemia. , 2000, 88, 352-357.		53
60	New and Old Treatment Modalities in Primary Myelofibrosis. <i>Cancer Journal (Sudbury, Mass )</i> , 2007, 13, 377-383.	1.0	53
61	Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. <i>Haematologica</i> , 2010, 95, 1317-1324.	1.7	53
62	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. <i>American Journal of Hematology</i> , 2020, 95, 156-166.	2.0	53
63	Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. <i>Leukemia Research</i> , 2011, 35, 1014-1019.	0.4	52
64	Liver Dysfunction following Splenectomy in Idiopathic Myelofibrosis: A Study of 10 Patients. <i>Acta Haematologica</i> , 1991, 85, 184-188.	0.7	50
65	Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. <i>Annals of Hematology</i> , 2008, 87, 269-276.	0.8	50
66	Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. <i>Journal of Hepatology</i> , 2017, 67, 501-507.	1.8	50
67	A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 1990, 76, 27-32.	1.2	49
68	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. <i>Blood</i> , 2014, 124, 405-405.	0.6	47
69	Transfusion dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis – prognostic relevance is independent of IPSS or karyotype. <i>American Journal of Hematology</i> , 2010, 85, 14-17.	2.0	46
70	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. <i>Haematologica</i> , 2017, 102, 85-93.	1.7	46
71	Management of Essential Thrombocythemia. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 215-221.	0.9	43
72	Modern management of myelofibrosis. <i>British Journal of Haematology</i> , 2005, 128, 583-592.	1.2	42

#	ARTICLE	IF	CITATIONS
73	A new prognostic system for multiple myeloma based on easily available parameters. <i>British Journal of Haematology</i> , 1989, 72, 507-511.	1.2	39
74	Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis. <i>Experimental Hematology</i> , 2003, 31, 204-210.	0.2	39
75	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. <i>Haematologica</i> , 2014, 99, 292-298.	1.7	38
76	Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 52-59.	2.0	38
77	Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. <i>Blood Cancer Journal</i> , 2018, 8, 91.	2.8	38
78	The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. <i>European Journal of Haematology</i> , 1998, 60, 101-105.	1.1	36
79	Prognosis of Chronic Myeloid Leukemia: Studies from the Barcelona Group. <i>Leukemia and Lymphoma</i> , 1993, 11, 63-66.	0.6	35
80	No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 843-850.	1.2	34
81	Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. <i>British Journal of Haematology</i> , 2018, 181, 397-400.	1.2	34
82	The value of detecting surface and cytoplasmic antigens in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1992, 81, 178-183.	1.2	33
83	Blood cell activation in myeloproliferative neoplasms. <i>Haematologica</i> , 2009, 94, 1484-1488.	1.7	33
84	Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF). <i>Blood</i> , 2012, 120, 801-801.	0.6	33
85	Systemic Lupus Erythematosus and Amyloidosis. <i>Arthritis and Rheumatism</i> , 1979, 22, 554-556.	6.7	31
86	Myelofibrosis with myeloid metaplasia: Disease overview and non-transplant treatment options. <i>Best Practice and Research in Clinical Haematology</i> , 2006, 19, 495-517.	0.7	31
87	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. <i>Haematologica</i> , 2018, 103, e392-e394.	1.7	31
88	Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. <i>European Journal of Haematology</i> , 2000, 65, 104-108.	1.1	30
89	Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. <i>Blood</i> , 2013, 122, 394-394.	0.6	29
90	Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. <i>Annals of Hematology</i> , 2017, 96, 81-85.	0.8	28

#	ARTICLE	IF	CITATIONS
91	Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. <i>European Journal of Haematology</i> , 2001, 66, 324-327.	1.1	26
92	Survivin expression in the progression of chronic myeloid leukemia: A sequential study in 16 patients. <i>Leukemia and Lymphoma</i> , 2005, 46, 717-722.	0.6	26
93	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2018, 8, 25.	2.8	26
94	Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. <i>Haematologica</i> , 2003, 88, 1117-22.	1.7	26
95	Bone marrow lymphoid nodules in myeloproliferative disorders: association with the nonmyelosclerotic phases of idiopathic myelofibrosis and immunological significance. <i>British Journal of Haematology</i> , 1988, 70, 279-282.	1.2	25
96	Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. <i>British Journal of Haematology</i> , 1994, 87, 293-300.	1.2	25
97	Bone marrow histopathology in primary myelofibrosis: Clinical and haematologic correlations and prognostic evaluation. <i>European Journal of Haematology</i> , 1990, 44, 95-99.	1.1	25
98	Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2021, 74, 89-95.	1.8	25
99	Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. <i>Leukemia</i> , 2021, 35, 3455-3465.	3.3	25
100	An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. <i>European Journal of Haematology</i> , 1996, 57, 286-291.	1.1	24
101	Use of the Functional Assessment of Cancer Therapy Anemia in Persons with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. <i>Clinical Therapeutics</i> , 2014, 36, 560-566.	1.1	24
102	Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis. <i>Blood</i> , 2015, 126, 825-825.	0.6	24
103	Myelofibrosis With Myeloid Metaplasia: Diagnosis, Prognostic Factors, and Staging. <i>Seminars in Oncology</i> , 2005, 32, 395-402.	0.8	23
104	Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. <i>European Journal of Haematology</i> , 2017, 98, 407-414.	1.1	23
105	Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. <i>British Journal of Haematology</i> , 2004, 124, 329-335.	1.2	22
106	Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , 2017, 178, 764-771.	1.2	22
107	Non-Hodgkin's Lymphoma Associated with Gaucher's Disease. <i>Leukemia and Lymphoma</i> , 1998, 31, 609-612.	0.6	21
108	Blast Crisis of Ph-Positive Chronic Myeloid Leukemia with Isochromosome 17q: Report of 12 Cases and Review of the Literature. <i>Leukemia and Lymphoma</i> , 2000, 38, 83-90.	0.6	21



#	ARTICLE	IF	CITATIONS
109	Practical management of patients with chronic myeloid leukemia. <i>Cancer</i> , 2011, 117, 4343-4354.	2.0	20
110	Prognostication in Primary Myelofibrosis. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 43-49.	1.2	19
111	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. <i>Leukemia Research</i> , 2017, 63, 34-40.	0.4	18
112	Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease. , 2000, 88, 2142-2148.		17
113	Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis. <i>Annals of Hematology</i> , 2020, 99, 791-798.	0.8	17
114	Is the histological classification of chronic granulocytic leukaemia justified from the clinical point of view?. <i>European Journal of Haematology</i> , 1989, 42, 150-154.	1.1	16
115	The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. <i>Cancer</i> , 2016, 122, 1888-1896.	2.0	16
116	Long-term results of prednisone treatment for the anemia of myelofibrosis. <i>Leukemia and Lymphoma</i> , 2016, 57, 120-124.	0.6	16
117	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. <i>Cancer Medicine</i> , 2019, 8, 4089-4092.	1.3	16
118	The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT). <i>Blood</i> , 2013, 122, 4070-4070.	0.6	15
119	Advances in the understanding and management of primary myelofibrosis. <i>Current Opinion in Oncology</i> , 2011, 23, 665-671.	1.1	14
120	Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors. <i>Biochemical Pharmacology</i> , 2018, 156, 248-264.	2.0	14
121	Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2237-2244.	2.0	14
122	Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7001-7001.	0.8	14
123	Alleviating anemia and thrombocytopenia in myelofibrosis patients. <i>Expert Review of Hematology</i> , 2016, 9, 489-496.	1.0	13
124	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. <i>Leukemia Research</i> , 2018, 69, 100-102.	0.4	13
125	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. <i>Blood Cancer Journal</i> , 2018, 8, 89.	2.8	13
126	Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. <i>Annals of Hematology</i> , 2019, 98, 2319-2328.	0.8	13



#	ARTICLE	IF	CITATIONS
127	Hypercalcemia in a Patient with Chronic Lymphocytic Leukemia Evolving into Richter's Syndrome. <i>Leukemia and Lymphoma</i> , 1996, 21, 521-523.	0.6	12
128	Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia. <i>Platelets</i> , 2012, 23, 336-343.	1.1	12
129	Myelofibrosis: an update on current pharmacotherapy and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 873-884.	0.9	12
130	Essential thrombocythaemia with mutation in <i>MPL</i> : clinicopathological correlation and comparison with <i>JAK2</i> V617F-mutated and <i>CALR</i> -mutated genotypes. <i>Journal of Clinical Pathology</i> , 2018, 71, 975-980.	1.0	12
131	Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea. <i>Leukemia</i> , 2021, 35, 623-627.	3.3	12
132	Pomalidomide Therapy in Myelofibrosis: 2-Year Follow-up of a Randomized Phase 2 Study. <i>Blood</i> , 2009, 114, 1904-1904.	0.6	12
133	Reductions in <i>JAK2</i> V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT). <i>Blood</i> , 2012, 120, 802-802.	0.6	12
134	Risk of relapse and clinicopathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment. <i>European Journal of Haematology</i> , 1998, 61, 59-64.	1.1	11
135	Iron stores in chronic granulocytic leukaemia at presentation. <i>Scandinavian Journal of Haematology</i> , 1984, 32, 469-474.	0.0	10
136	Relationship between the 46/1 haplotype of the <i>JAK2</i> gene and the <i>JAK2</i> mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis. <i>Annals of Hematology</i> , 2014, 93, 797-802.	0.8	10
137	Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms. <i>Blood</i> , 2013, 122, 4068-4068.	0.6	10
138	Multiple Myeloma Following Essential Thrombocythemia. <i>Leukemia and Lymphoma</i> , 1995, 20, 177-179.	0.6	9
139	Hypercalcemia as the Presenting Feature of T-Cell Lymphoid Blast Crisis of Ph-Positive Chronic Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2001, 41, 203-206.	0.6	9
140	Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2003, 120, 500-504.	1.2	9
141	Acute transformation of chronic myelomonocytic leukaemia: a multivariate study of predictive factors. <i>European Journal of Haematology</i> , 1989, 42, 284-288.	1.1	9
142	Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). <i>Blood</i> , 2013, 122, 4087-4087.	0.6	9
143	Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients. <i>Blood</i> , 2014, 124, 1824-1824.	0.6	9
144	Successful autografting in chronic myelogenous leukaemia using Philadelphia negative blood progenitor cells mobilized with rHuG-CSF alone in a patient responding to alpha-interferon. <i>British Journal of Haematology</i> , 1997, 96, 421-423.	1.2	8

#	ARTICLE	IF	CITATIONS
145	Early Tâ€cell features in blast crisis of Ph<sup>1</sup>â€positive chronic myeloid leukaemia. Scandinavian Journal of Haematology, 1985, 35, 71-76.	0.0	8
146	Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain. Journal of Medical Economics, 2014, 17, 435-441.	1.0	8
147	Impact of bone marrow fibrosis grade in postâ€polycythemia vera and postâ€essential thrombocythemia myelofibrosis: A study of the MYSEC group. American Journal of Hematology, 2020, 95, E1-E3.	2.0	8
148	Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD.. Blood, 2006, 108, 377-377.	0.6	8
149	Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis. Blood, 2014, 124, 712-712.	0.6	8
150	Momelotinib reduces transfusion requirements in patients with myelofibrosis. Leukemia and Lymphoma, 2022, 63, 1718-1722.	0.6	8
151	Non-Hodgkin's Lymphoma Following Untreated Essential Thrombocythemia. Leukemia and Lymphoma, 2000, 36, 421-423.	0.6	7
152	Myelofibrosis: biology and treatment options. European Journal of Haematology, 2007, 79, 13-17.	1.1	7
153	Novel therapies for myelofibrosis. Leukemia and Lymphoma, 2015, 56, 2768-2778.	0.6	7
154	BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia. Leukemia Research, 2015, 39, 1278-1284.	0.4	7
155	Prognostic risk models for transplant decision-making in myelofibrosis. Annals of Hematology, 2018, 97, 813-820.	0.8	7
156	Detection of inflammatory monocytes but not mesenchymal stem/stromal cells in peripheral blood of patients with myelofibrosis. British Journal of Haematology, 2018, 181, 133-137.	1.2	7
157	Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. Blood Advances, 2020, 4, 3063-3071.	2.5	7
158	Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results. Blood, 2015, 126, 59-59.	0.6	7
159	A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF). Blood, 2016, 128, 3110-3110.	0.6	7
160	A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2). Blood, 2021, 138, 3643-3643.	0.6	7
161	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. Blood, 2013, 122, 4067-4067.	0.6	6
162	Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). Blood, 2013, 122, 4088-4088.	0.6	6

#	ARTICLE	IF	CITATIONS
163	Survival and Prognosis in Patients with First-Line Imatinib Treatment Under Particular Consideration of Death Due to Chronic Myeloid Leukemia. <i>Blood</i> , 2014, 124, 153-153.	0.6	6
164	Association of cytokine levels and reductions in spleen size in COMFORT-II, a phase III study comparing ruxolitinib to best available therapy (BAT).. <i>Journal of Clinical Oncology</i> , 2012, 30, 6625-6625.	0.8	6
165	Relationship Between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and Efficacy in Patients with Myelofibrosis in the Phase III Persist-1 Trial of Pacritinib Vs. Best Available Therapy (BAT). <i>Blood</i> , 2015, 126, 1609-1609.	0.6	6
166	Non-hodgkin's lymphoma of unfavourable histology: A multivariate analysis of factors predicting the response to chop. <i>Hematological Oncology</i> , 2006, 5, 203-211.	0.8	5
167	Conventional and molecular cytogenetic studies to characterize 2 complex variant Philadelphia translocations in patients with chronic myeloid leukemia. <i>Oncology Letters</i> , 2019, 17, 5705-5710.	0.8	5
168	Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Na <sup>+</sup> ve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib. <i>Blood</i> , 2019, 134, 1663-1663.	0.6	5
169	Reductions in <i>JAK2</i> V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT).. <i>Journal of Clinical Oncology</i> , 2012, 30, 6514-6514.	0.8	5
170	Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6626-6626.	0.8	5
171	Scleroderma Associated with Idiopathic Myelofibrosis. <i>Leukemia and Lymphoma</i> , 1990, 1, 153-155.	0.6	4
172	The <i>ERCC2</i> G/G polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis. <i>British Journal of Haematology</i> , 2013, 162, 424-427.	1.2	4
173	A New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment. <i>Blood</i> , 2008, 112, 657-657.	0.6	4
174	Pomalidomide Therapy in Anemic Patients with Myelofibrosis: Results from a Phase-2 Randomized Multicenter Study. <i>Blood</i> , 2008, 112, 663-663.	0.6	4
175	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs).. <i>Blood</i> , 2011, 118, 3839-3839.	0.6	4
176	Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study). <i>Blood</i> , 2014, 124, 1849-1849.	0.6	4
177	Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group. <i>Blood</i> , 2016, 128, 3117-3117.	0.6	4
178	Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7000-7000.	0.8	4
179	Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients. <i>Blood</i> , 2012, 120, 1726-1726.	0.6	4
180	Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms. <i>European Journal of Haematology</i> , 2017, 99, 36-41.	1.1	3

#	ARTICLE	IF	CITATIONS
181	Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 152-158.	0.1	3
182	Características clínico-biológicas de los pacientes con mielofibrosis: un análisis de 1.000 casos del Registro Español de Mielofibrosis. <i>Medicina Clínica</i> , 2020, 155, 152-158.	0.3	3
183	Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After ≥ 2 Years On Imatinib: ENestcmr 2-Year Follow-up Results. <i>Blood</i> , 2012, 120, 694-694.	0.6	3
184	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. <i>Blood</i> , 2013, 122, 104-104.	0.6	3
185	Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL). <i>Blood</i> , 2015, 126, 4029-4029.	0.6	3
186	Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs. <i>Blood</i> , 2015, 126, 4080-4080.	0.6	3
187	The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 595-595.	0.6	3
188	Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6505-6505.	0.8	3
189	The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients. <i>Blood</i> , 2012, 120, 1731-1731.	0.6	2
190	Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use: a Retrospective Evaluation of 1334 Patients. <i>Blood</i> , 2014, 124, 1848-1848.	0.6	2
191	A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr-Mutated Low Risk Essential Thrombocythemia. <i>Blood</i> , 2015, 126, 1602-1602.	0.6	2
192	Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs). <i>Blood</i> , 2015, 126, 4073-4073.	0.6	2
193	Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial. <i>Blood</i> , 2015, 126, 58-58.	0.6	2
194	Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up. <i>Blood</i> , 2013, 122, 94-95.	0.6	2
195	Excess Mortality in Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2018, 132, 3042-3042.	0.6	2
196	Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. <i>Cancers</i> , 2022, 14, 2331.	1.7	2
197	Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients. <i>Blood</i> , 2018, 132, 47-47.	0.6	1
198	Thrombosis in Primary Myelofibrosis: Incidence and Risk Factors.. <i>Blood</i> , 2009, 114, 2915-2915.	0.6	1

#	ARTICLE	IF	CITATIONS
199	Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasms. A Study Of The IWG-MRT In 475 Subjects. <i>Blood</i> , 2013, 122, 1582-1582.	0.6	1
200	CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry. <i>Blood</i> , 2013, 122, 2735-2735.	0.6	1
201	Impact Of Ruxolitinib On The Natural History Of Patients With Primary Myelofibrosis: A Retrospective Comparison Of The DIPSS and The Comfort-2 Cohorts. <i>Blood</i> , 2013, 122, 4066-4066.	0.6	1
202	Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects. <i>Blood</i> , 2014, 124, 3163-3163.	0.6	1
203	Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials. <i>Blood</i> , 2016, 128, 3118-3118.	0.6	1
204	JAKARTA: A phase III, multicenter, randomized, double-blind, placebo-controlled, three-arm study of SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF with splenomegaly.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS6639-TPS6639.	0.8	1
205	Effect of continued imatinib (IM) in pts with detectable BCR-ABL after 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7025-7025.	0.8	1
206	Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Long-term follow-up of patient-reported outcomes (PROs) in the phase III PERSIST-1 trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7067-7067.	0.8	1
207	DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status. <i>Blood</i> , 2010, 116, 4104-4104.	0.6	1
208	Prediction of Overall Survival in 520 Patients with Primary Myelofibrosis: Outcome Update of the Dynamic International Prognostic Scoring System (DIPSS) Patient Cohort. <i>Blood</i> , 2012, 120, 1729-1729.	0.6	1
209	Assessment of Iron Stores in Hospitalized Patients. <i>American Journal of Clinical Pathology</i> , 1991, 95, 105-106.	0.4	0
210	A multivariate analysis of prognostic factors in chronic myelomonocytic leukaemia according to the FAB criteria. <i>British Journal of Haematology</i> , 1987, 65, 307-311.	1.2	0
211	Conventional and New Treatment Modalities in Myelofibrosis and the Current Role of Transplantation. <i>Clinical Leukemia</i> , 2008, 2, 39-45.	0.2	0
212	Response: Capturing variables with prognostic relevance in development of a new scoring system for primary myelofibrosis. <i>Blood</i> , 2010, 115, 745-746.	0.6	0
213	Accurately assessing risk in your myeloproliferative neoplasm patient. , 0, , 37-44.		0
214	Reply to: Correspondence on Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2021, 74, 252-254.	1.8	0
215	Tissue Factor and Soluble Markers of Platelet and Endothelial Activation in Essential Thrombocythemia: Relationship with Thrombosis and JAK2 V617F Mutation Status.. <i>Blood</i> , 2006, 108, 2707-2707.	0.6	0
216	Essential Thrombocythemia in Young Individuals: Frequency and Risk Factors for Vascular Events and Evolution to Myelofibrosis in 126 Patients.. <i>Blood</i> , 2006, 108, 3598-3598.	0.6	0

#	ARTICLE	IF	CITATIONS
217	JAK2 Mutations at Exon 12 and 14 in Polycythemia Vera and Idiopathic Erythrocytosis: Incidence and Correlation with Clinical Characteristics.. Blood, 2007, 110, 2532-2532.	0.6	0
218	Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with JAK2 and TET2 Mutational Status.. Blood, 2009, 114, 1909-1909.	0.6	0
219	A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: a Study of the International Working Group for Myeloproliferative Neoplasm Research and Treatment (IWG-MRT).. Blood, 2009, 114, 3891-3891.	0.6	0
220	Platelet Antiaggregant Therapy Prevents Venous Thrombosis in Patients with JAK2 V617F Positive Essential Thrombocythemia without Indication of Cytoreductive Treatment.. Blood, 2009, 114, 3906-3906.	0.6	0
221	Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group.. Blood, 2009, 114, 1113-1113.	0.6	0
222	Prognostic Factors in Classic Myeloproliferative Neoplasms. , 2011, , 85-96.		0
223	Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry. Blood, 2011, 118, 1688-1688.	0.6	0
224	Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study,. Blood, 2011, 118, 3833-3833.	0.6	0
225	Patient's Information and Examinations Needed Before Planning Therapy in the Myeloproliferative Neoplasms. , 2012, , 47-55.		0
226	Cytoreduction Plus Low-Dose Aspirin Versus Cytoreduction in Monotherapy As Primary Prophylaxis of Thrombosis in Patients with Essential Thrombocythemia.. Blood, 2012, 120, 2828-2828.	0.6	0
227	Comparison of the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients.. Blood, 2012, 120, 2852-2852.	0.6	0
228	BAALC-Associated Mir-3151 Is An Independent Prognostic Factor In Younger Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia. Blood, 2013, 122, 2577-2577.	0.6	0
229	Overall Survival and Prognosis In Patients With First-Line Imatinib Treatment Under Consideration Of Death Due To Any Cause and Death Due To Chronic Myeloid Leukemia Only. Blood, 2013, 122, 382-382.	0.6	0
230	Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients. Blood, 2014, 124, 633-633.	0.6	0
231	Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression. Blood, 2014, 124, 3187-3187.	0.6	0
232	Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy. Blood, 2015, 126, 5175-5175.	0.6	0
233	The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor: A phase 2, randomized study.. Journal of Clinical Oncology, 2016, 34, TPS7079-TPS7079.	0.8	0
234	Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group. Blood, 2016, 128, 5463-5463.	0.6	0



#	ARTICLE	IF	CITATIONS
235	Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2). Blood, 2018, 132, 4281-4281.	0.6	0
236	Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations. Blood, 2018, 132, 4299-4299.	0.6	0
237	Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients. Blood, 2018, 132, 3039-3039.	0.6	0
238	Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome. Blood, 2019, 134, 2952-2952.	0.6	0
239	Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group. Blood, 2019, 134, 2946-2946.	0.6	0